海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
- Hemophilia A Severe hemophilia A MedDRA version: 20.0 Level: LLT Classification code 10060613 Term: Hemophilia A (Factor VIII) System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Austria, Canada, Czech Republic, European Union, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, South Africa, Spain, Switzerland, Thailand, Ukraine, United Kingdom, United States
- 2014-05-06
Authorised
- A Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
- Hemophilia A MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, Dominican Republic, Finland, Germany, Guatemala, Hungary, Israel, Italy, Mexico, Netherlands, Panama, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Sweden, Switzerland, United Kingdom
- 2017-06-12
Authorised
- A clinical trial to determine the most suitable dose of a combination of eribulin and capecitabine for use in late stage breast cancer patients
- Phase 1 - Advanced and/or metastatic cancer Phase 2 - Advanced and/or metastatic breast cancer MedDRA version: 17.0 Level: LLT Classification code 10027477 Term: Metastatic carcinoma System Organ Class: 100000004864 MedDRA version: 17.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Bulgaria, Russian Federation, United Kingdom
- 2009-08-21
Authorised
- Safety and efficacy study in patients with untreated follicular non-Hodgkin´s lymphoma.
- Untreated stage III or IV non-Hodgkin’s lymphoma (CD20+ Follicular Lymphoma of Grade 1, 2 or 3a, requiring chemotherapy) MedDRA version: 14.1 Level: HLT Classification code 10016903 Term: Follicle centre lymphomas, follicular grade I, II, III System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Chile, Croatia, Czech Republic, Denmark, Egypt, France, Germany, Guatemala, Hong Kong, Hungary, India, Indonesia, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Panama, Peru, Philippines, Poland, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sri Lanka, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
- 2011-12-06
Authorised
- A TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE OPTIC NEUROPATHY (NAION)
- NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in NAION is thought to occur as primary retinal ganglion cell (RGC) axonal and glial damage from ischemia; Damage to RGC axons causes retrograde death of the associated RGC soma by apoptosis, Neuroprotection of partially damaged RGCs would further limit the loss of visual function MedDRA version: 20.0 Level: LLT Classification code 10068242 Term: Nonarteritic anterior ischaemic optic neuropathy System Organ Class: 100000014125 ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Australia, China, Germany, India, Israel, Italy, United States
- 2016-07-21
Authorised
- International clinical trial to determine whether treatment with RVX000222 as compared to placebo increases time to occurrence of cardiac events in patients with Diabetes Mellitus and with a history of atherosclerotic cardiovascular disease.
- Secondary cardiovascular disease (CVD) prevention in type 2 diabetes mellitus (T2DM) subjects with low high-density lipoprotein cholesterol (HDL-C) at high risk for MACE. MedDRA version: 19.0 Level: LLT Classification code 10051614 Term: Arteriosclerotic cardiovascular disease System Organ Class: 100000004866 MedDRA version: 19.0 Level: LLT Classification code 10051615 Term: Atherosclerotic cardiovascular disease System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Australia, Belgium, Bulgaria, Croatia, Germany, Hungary, Israel, Mexico, Poland, Serbia, Slovakia
- 2015-08-17
Authorised
- Gene Therapy in patients with Mucopolysaccharidosis disease
- The clinical trial will be conducted on patients with Mucopolysaccharidosis Type VI. MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvement;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Italy, Netherlands, Turkey
- 2018-11-07
Authorised
- CLCZ696B2319E1 open-label extension (OLE) study to evaluate long-term safety and tolerability of sacubitril/valsartan in pediatric patients with heart failure
- Pediatric heart failure : Patients (= 13 months) with HF due to systemic left ventricular systolic dysfunction. [Note: All patients per protocol for the core study CLCZ696B2319 (PANORAMA-HF) are to be 1 yr older when they are potentially eligible for entry in the OLE Study CLCZ696B2319E1]. Subjects who turned 18 yrs old during the PANORAMA-HF study, and who qualify, are eligible to participate in the OLE study. Ref section F.1.2 MedDRA version: 20.0 Level: LLT Classification code 10019279 Term: Heart failure System Organ Class: 100000004849 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Austria, Belgium, Bulgaria, Canada, China, Croatia, Czech Republic, Egypt, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Jordan, Korea, Republic of, Lebanon, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2019-06-05
Authorised
- An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors
- Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or for which there is no alternative therapy known to prolong survival. MedDRA version: 20.0 Level: PT Classification code 10062042 Term: Lung neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10055108 Term: Thymic cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10072737 Term: Advanced breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10039491 Term: Sarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10043670 Term: Thymoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Brazil, Canada, China, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Russian Federation, Spain, Switzerland, Turkey, United Kingdom, United States
- 2015-04-01
Authorised
- A clinical trial to compare the efficacy and safety of AG-221 (CC-90007) versus conventional treatment on older subjects with late stage acute myeloid leukemia harboring an Isocitrate Dehydrogenase 2 Mutation
- Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mutation MedDRA version: 20.0 Level: LLT Classification code 10060558 Term: Acute myeloid leukemia recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Spain, United Kingdom, United States
- 2015-10-06
